Skip to content

Use of anti-inflammatory eye drops after laser therapy for glaucoma treatment

Use of anti-inflammatory eye drops after selective laser trabeculoplasty: a randomized clinical trial

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
REBEC
Registry ID
RBR-4ttd9yc
Enrollment
Unknown
Registered
2022-04-04
Start date
2022-05-01
Completion date
Unknown
Last updated
2025-10-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

primary open-angle glaucoma

Interventions

Patients with primary open angle glaucoma (POAG), ocular hypertension (OH), pseudoexfoliative glaucoma, pigmentary glaucoma or patients with pigment dispersion syndrome, with inadequate control of int
Group 2. 40 patients will be instructed to use 1% prednisolone acetate eye drops 4 times a day for 7 days after SLT
Group 3. 40 patients will be instructed to use 0.1% prednisolone acetate eye drops 4 times a day for 7 days after SLT
Group 4. 40 patients will be instructed to use 0.1% nepafenac eye drops 4 times a day for 7 days after SLT. Data on IOP, number of eye drops and complications will be obtained at intervals: 7 days, 30

Sponsors

Hospital Oftalmológico de Brasília
Lead Sponsor
Hospital Oftalmológico de Brasília
Collaborator

Eligibility

Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: Patients with primary open-angle glaucoma or ocular hypertension or pseudoexfoliative glaucoma or pigmentary glaucoma or pigment dispersion syndrome, with inadequate control of intraocular pressure or intolerance to topical treatment, that will undergo selective laser trabeculoplasty (SLT). Patients approached must be at least 18 years of age on the date of the procedure and be able to undergo post-SLT follow-up for at least 12 months

Exclusion criteria

Exclusion criteria: Angle-closure glaucoma; Any previous glaucoma surgery; Any previous corneal procedure (refractive surgery, intrastromal rings, corneal transplant); Pregnant women

Design outcomes

Primary

MeasureTime frame
To assess the success of selective laser trabeculoplasty (SLT) at the end of follow-up. The definition of success will be a 20% reduction in pre laser baseline intraocular pressure (IOP) and IOP less than 21mmHg. Failure criteria will be: failure to reach previously defined IOP values and need for retreatment, or need for glaucoma surgery during follow-up

Secondary

MeasureTime frame
Secondary outcomes will include changes in visual field and visual acuity (VA) and post selective laser trabeculoplasty (SLT) mean deviation (MD). In addition, we will assess predictors of success and complication rate. The pressure reduction obtained with the use of pilocarpine eye drops prior to SLT will be used as a predictor of SLT success

Countries

Brazil

Contacts

Public ContactLaura Oltramari

Hospital Oftalmológico de Brasília

lalaoltramari@hotmail.com+55 (51) 999669403

Outcome results

None listed

Source: REBEC (via WHO ICTRP)